Andrew Armstrong

Overview:

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

Positions:

Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Professor in Surgery

Surgery, Urology
School of Medicine

Professor in Pharmacology and Cancer Biology

Pharmacology & Cancer Biology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.S.E. 1996

Duke University

M.D. 2000

University of Virginia School of Medicine

M.Sc. 2008

Johns Hopkins University

Internship/Residency, General Internal Medicine

University of Pennsylvania, School of Medicine

Fellowship, Division Of Oncology/Hematology

Johns Hopkins University School of Medicine

Grants:

Study title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer

Administered By
Duke Cancer Institute
Awarded By
AstraZeneca AB
Role
Principal Investigator
Start Date
End Date

ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

Administered By
Duke Cancer Institute
Awarded By
Constellation Pharmaceuticals
Role
Principal Investigator
Start Date
End Date

VISION: An International, Prospective, Open-Label, Multicenter, Randomized Phase 3 Study of 177lu-Psma-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Administered By
Duke Cancer Institute
Awarded By
Endocyte, Inc.
Role
Principal Investigator
Start Date
End Date

A Phase 2 Study of Nivolumab in combination with either Rucaparib, docetaxel, or enzalutamide in men with Castration-resistant metastaic prostate cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMA

Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Role
Principal Investigator
Start Date
End Date

A Phase II Study of Navarixin (MK-7123) in Combination with Pembrolizumab (MK-3475) in Participants with Selected Advanced/Metastatic Solid Tumors

Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Role
Principal Investigator
Start Date
End Date

Publications:

1475P Association of circulating tumor cells (CTCs) with immune checkpoint inhibitor (ICI) responses in metastatic renal cell carcinoma (mRCC)

Authors
Zhang, T; Poellmann, M; Park, S-J; Bu, J; Zhao, R; Zhou, Q; Agarwal, A; Parks, J; Reyes-Martinez, M; Armstrong, AJ; George, DJ; Wang, AZ; Hong, S
MLA Citation
Zhang, T., et al. “1475P Association of circulating tumor cells (CTCs) with immune checkpoint inhibitor (ICI) responses in metastatic renal cell carcinoma (mRCC).” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1221–S1221. Crossref, doi:10.1016/j.annonc.2022.07.1578.
URI
https://scholars.duke.edu/individual/pub1559928
Source
crossref
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S1221
End Page
S1221
DOI
10.1016/j.annonc.2022.07.1578

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.

BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. OBJECTIVE: To present consensus voting results for select questions from APCCC 2022. DESIGN, SETTING, AND PARTICIPANTS: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. RESULTS AND LIMITATIONS: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. CONCLUSIONS: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers prioritise areas for future research. Diagnostic and treatment decisions should always be individualised based on patient and cancer characteristics (disease extent and location, treatment history, comorbidities, and patient preferences) and should incorporate current and emerging clinical evidence, therapeutic guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2022 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials. PATIENT SUMMARY: The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with health care providers and patients worldwide. At each APCCC, a panel of physician experts vote in response to multiple-choice questions about their clinical opinions and approaches to managing advanced prostate cancer. This report presents voting results for the subset of questions pertaining to intermediate- and high-risk and locally advanced prostate cancer, biochemical relapse after definitive treatment, advanced (next-generation) imaging, and management of side effects caused by hormonal therapies. The results provide a practical guide to help clinicians and patients discuss treatment options as part of shared multidisciplinary decision-making. The findings may be especially useful when there is little or no high-level evidence to guide treatment decisions.
Authors
Gillessen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; James, ND; Mottet, N; Shore, N; Small, E; Smith, M; Sweeney, C; Tombal, B; Antonarakis, ES; Aparicio, AM; Armstrong, AJ; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Blanchard, P; Briganti, A; Bristow, RG; Bulbul, M; Caffo, O; Castellano, D; Castro, E; Cheng, HH; Chi, KN; Chowdhury, S; Clarke, CS; Clarke, N; Daugaard, G; De Santis, M; Duran, I; Eeles, R; Efstathiou, E; Efstathiou, J; Ngozi Ekeke, O; Evans, CP; Fanti, S; Feng, FY; Fonteyne, V; Fossati, N; Frydenberg, M; George, D; Gleave, M; Gravis, G; Halabi, S; Heinrich, D; Herrmann, K; Higano, C; Hofman, MS; Horvath, LG; Hussain, M; Alicja Jereczek-Fossa, B; Jones, R; Kanesvaran, R; Kellokumpu-Lehtinen, P-L; Khauli, RB; Klotz, L; Kramer, G; Leibowitz, R; Logothetis, CJ; Mahal, BA; Maluf, F; Mateo, J; Matheson, D; Mehra, N; Merseburger, A; Morgans, AK; Morris, MJ; Mrabti, H; Mukherji, D; Murphy, DG; Murthy, V; Nguyen, PL; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Pezaro, C; Poon, DMC; Pritchard, CC; Rabah, DM; Rathkopf, D; Reiter, RE; Rubin, MA; Ryan, CJ; Saad, F; Pablo Sade, J; Sartor, OA; Scher, HI; Sharifi, N; Skoneczna, I; Soule, H; Spratt, DE; Srinivas, S; Sternberg, CN; Steuber, T; Suzuki, H; Sydes, MR; Taplin, M-E; Tilki, D; Türkeri, L; Turco, F; Uemura, H; Uemura, H; Ürün, Y; Vale, CL; van Oort, I; Vapiwala, N; Walz, J; Yamoah, K; Ye, D; Yu, EY; Zapatero, A; Zilli, T; Omlin, A
URI
https://scholars.duke.edu/individual/pub1559016
PMID
36494221
Source
pubmed
Published In
Eur Urol
Published Date
DOI
10.1016/j.eururo.2022.11.002

Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post h

Authors
Petrylak, DP; Azad, AA; Szmulewitz, RZ; Iguchi, T; Shore, ND; Holzbeierlein, J; Alekseev, B; El-Chaar, NN; Rosbrook, B; Ma, J; Zohren, F; Haas, GP; Stenzl, A; Armstrong, AJ
URI
https://scholars.duke.edu/individual/pub1559925
Source
wos-lite
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S1183
End Page
S1184

The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)

Authors
Gupta, S; Yang, Q; Halabi, S; Tubbs, A; Gore, Y; George, DJ; Nanus, DM; Antonarakis, ES; Danila, D; Szmulewitz, R; Wenstrup, RJ; Armstrong, AJ
MLA Citation
Gupta, S., et al. “The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC).” Annals of Oncology, vol. 33, no. 7, 2022, pp. S1165–66.
URI
https://scholars.duke.edu/individual/pub1559926
Source
wos-lite
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S1165
End Page
S1166

Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castrationresistant prostate cancer in the VISION trial

Authors
Armstrong, AJ; Sartor, O; Saad, F; Czernin, J; Shore, ND; Kendi, AT; Beer, TM; Vaishampayan, N; El-Haddad, G; Wu, J; Mirante, O; Morris, MJ
URI
https://scholars.duke.edu/individual/pub1559927
Source
wos-lite
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S1169
End Page
S1170